Cargando…

Cancer immunotherapy by immunosuppression

We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing...

Descripción completa

Detalles Bibliográficos
Autores principales: Prehn, Richmond T, Prehn, Liisa M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018371/
https://www.ncbi.nlm.nih.gov/pubmed/21159199
http://dx.doi.org/10.1186/1742-4682-7-45
_version_ 1782196049441456128
author Prehn, Richmond T
Prehn, Liisa M
author_facet Prehn, Richmond T
Prehn, Liisa M
author_sort Prehn, Richmond T
collection PubMed
description We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing cancer, whether in man or mouse, is throughout its lifespan, probably growing and progressing because of continued immune stimulation by a weak immune reaction. We also suggest that prolonged immunosuppression might interfere with progression and thus be an aid to therapy. While most of the considerable evidence that supports the hypothesis comes from observations of experimental mouse tumors, there is suggestive evidence that human tumors may behave in much the same way, and as far as we can ascertain, there is no present evidence that necessarily refutes the hypothesis.
format Text
id pubmed-3018371
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30183712011-01-11 Cancer immunotherapy by immunosuppression Prehn, Richmond T Prehn, Liisa M Theor Biol Med Model Commentary We have previously suggested that the stimulatory effect of a weak immune reaction on tumor growth may be necessary for the growth of incipient tumors. In the present paper, we enlarge upon and extend that idea by collecting evidence in the literature bearing upon this new hypothesis that a growing cancer, whether in man or mouse, is throughout its lifespan, probably growing and progressing because of continued immune stimulation by a weak immune reaction. We also suggest that prolonged immunosuppression might interfere with progression and thus be an aid to therapy. While most of the considerable evidence that supports the hypothesis comes from observations of experimental mouse tumors, there is suggestive evidence that human tumors may behave in much the same way, and as far as we can ascertain, there is no present evidence that necessarily refutes the hypothesis. BioMed Central 2010-12-15 /pmc/articles/PMC3018371/ /pubmed/21159199 http://dx.doi.org/10.1186/1742-4682-7-45 Text en Copyright ©2010 Prehn and Prehn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Prehn, Richmond T
Prehn, Liisa M
Cancer immunotherapy by immunosuppression
title Cancer immunotherapy by immunosuppression
title_full Cancer immunotherapy by immunosuppression
title_fullStr Cancer immunotherapy by immunosuppression
title_full_unstemmed Cancer immunotherapy by immunosuppression
title_short Cancer immunotherapy by immunosuppression
title_sort cancer immunotherapy by immunosuppression
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018371/
https://www.ncbi.nlm.nih.gov/pubmed/21159199
http://dx.doi.org/10.1186/1742-4682-7-45
work_keys_str_mv AT prehnrichmondt cancerimmunotherapybyimmunosuppression
AT prehnliisam cancerimmunotherapybyimmunosuppression